-
2022-501810-77-00
5
2023-09-01
Relapsed or Refractory Marginal Zone Lymphoma
-
2022-501943-34-00
5
2023-06-27
Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
-
2022-501494-39-00
5
2023-03-28
Uncontrolled Hypertension IN patients with moderate to severe chronic
-
2022-500520-30-00
5
2023-03-01
neurology
-
2022-501335-16-00
10
2023-01-16
Interstitial lung disease
-
2022-502687-20-00
4
2022-09-14
Wilms tumor
-
2024-511822-30-00
11
2021-09-22
Crohn’s disease
-
2024-514094-22-00
5
2019-01-18
Intrecerebral Haemorrhage
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-518578-15-00
5
2018-02-05
Is to demonstrate a non inferior efficacy of azithromycin and so the p
-
2024-518339-12-00
4
2025-07-08
Idiopathic Pulmonary Fibrosis
-
2024-511754-41-00
4
2025-05-29
idiopathic pulmonary fibrosis
-
2024-517169-18-00
5
2025-04-10
Multiple System Atrophy
-
2024-512998-27-00
5
2025-02-21
Non-Small Cell Lung Cancer
-
2023-504176-25-00
9
2024-08-08
Acute Myeloid Leukemia
-
2022-501372-25-00
4
2024-01-10
Patients aged 18 years and older with relapsed or refractory FLT3 muta
-
2022-501608-85-00
5
2023-05-09
Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
-
2022-501179-23-00
6
2023-03-08
atopic dermatitis
-
2024-515845-40-00
5
2022-11-22
Acute kidney injury
-
2023-503999-24-00
5
2022-06-01
Patients With Locally Advanced (Stage III), Unresectable Non-small Cel
-
2024-515944-22-00
4
2021-01-19
BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
-
2024-515331-30-00
7
2020-10-30
Primary Central Nervous System Lymphoma (PCNSL)
-
2022-501974-21-00
5
2020-04-01
Prevention of oral persistent infection caused by any of the human pap